Skip to main content
Media RelationsInvestor RelationsHome
Logo SphingotecLogo Sphingotec

Investor Relations

We aim to sustain continuous, clear, and trustful communication with all our partners and stakeholders.

Innovative diagnostic solutions for acute and critical care conditions

We are committed to improving patient outcomes with innovative diagnostic solutions for acute and critical care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.

SphingoTec develops and markets innovative IVD solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements to routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such as sepsis, acute heart failure, and acute kidney injury.

SphingoTec is a privately held company with a long history of biomarker discovery, development and validation. We are the legal manufacturer of the CE IVD microtiter plate assays. Committed to providing solutions that meet and exceed customer and regulatory requirements, we manufacture our products in accordance with EN ISO 13485:2016.

 

Our investors share our vision of improving patient outcomes

Working medical staff in intensive care unit.

SphingoTec in a nutshell

Our portfolio of tests supports better management of critically ill patients, where fast and reliable information is essential in taking treatment decisions. The solutions we have created combine scientific discoveries with medical research and robust technologies to support clinicians in improving disease management. We work together with internationally leading academic and non-academic medical centers, as well as with global IVD and pharma companies to bring these innovations closer to the patients. 

Investment Thesis

Global expansion

Through strategic partnerships and out-licensing of our biomarkers, we aim at making the innovations worldwide available.

Early stage opportunity

An opportunity of investment in more than 200 patents that could benefit over 60 million patients worldwide.

Skillful team

A skilled international team with a broad scope of experience committed to improve patient lives

An innovative portfolio

Innovative biomarkers for diagnosis, outcome prediction, and monitoring of mortality drivers in the intensive care unit.

Latest News

View all News

06. May 2025

Boditech Med and SphingoTec Announce Launch of AFIAS penKid® Assay for Kidney Function Diagnostics

Boditech Med Inc. and SphingoTec GmbHtoday announced the commercial launch of the AFIAS sphingotest® penKid® assay.
Read more
16. April 2025

Beyond Creatinine: First Real-World Evidence Highlights Proenkephalin A 119–159 (penKid) as a Valuable Kidney Function Biomarker

Proenkephalin A 119–159 (penKid) has been successfully integrated into daily practice in intensive care unit (ICU), demonstrating its effectiveness in assessing kidney function and predicting acute kidney injury (AKI) in over 4,000 patients.
Read more
09. January 2025

Assessing Post-Cardiac Surgery Kidney Recovery Through PenKid's Emerging Role in Renal Replacement Therapy Decisions

Results from the first prospective study, conducted at the Medical University of Vienna, demonstrating penKid as a discriminatory biomarker for successful liberation from CRRT in cardiac surgery patients with acute kidney injury.
Read more

Events & Expos

View all Events

04. - 06. December 2024

15:21 - 15:22

Hamburg, Germany

24. KONGRESS DER DEUTSCHEN INTERDISZIPLINÄREN VEREINIGUNG FÜR INTENSIV- UND NOTFALLMEDIZIN E.V. (DIVI)

The 24th Congress of The German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI) is a conference dedicated to practical and scientific topics related to intensive care and…

Read more
11. - 13. June 2024

15:21 - 15:22

Vicenza, Italy

42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology 2024

In the 2024 edition of the course, special attention will be placed on the new developments in the areas of technology, pharmacology, clinical trials and consensus definitions in critical care…

Read more
19. - 22. March 2024

15:21 - 15:22

Brussels, Belgium

43rd International Symposium on Intensive Care and Emergency Medicine (ISICEM)

The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Université Libre de…

Read more

Contact Investor Relations

Do you have any questions or require more information? Please contact the Investor Relations Team, send us an e-mail or call us.

phone: + 49 (0)330 220 56 5 - 0
email: investor.relations@sphingotec.com

Nicole Witzmann

Chief Financial Officer

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now